ERAS with or without supplemental artificial nutrition in open pancreatoduodenectomy for cancer. A multicenter, randomized, open labeled trial (RASTA study protocol).

ERAS artificial nutrition complication outcome pancreatoduodenectomy randomized controlled trial

Journal

Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264

Informations de publication

Date de publication:
2023
Historique:
received: 01 12 2022
accepted: 13 03 2023
medline: 14 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: epublish

Résumé

The role of supplemental artificial nutrition in patients perioperatively treated according to enhanced recovery programs (ERAS) on surgery-related morbidity is not known. Therefore, there is a need of a clinical trials specifically designed to explore whether given a full nutritional requirement by parenteral feeding after surgery coupled with oral food "at will" compared to oral food "at will" alone, within an established ERAS program, could achieve a reduction of the morbidity burden. RASTA will be a multicenter, randomized, parallel-arm, open labeled, superiority trial. The trial will be conducted in five Italian Institutions with proven experience in pancreatic surgery and already applying an established ERAS program. Adult patients (age ≥ 18 and < 90 years of age) candidate to elective open pancreatoduodenectomy (PD) for any periampullary or pancreatic cancer will be randomized to receive a full ERAS protocol that establishes oral food "at will" plus parenteral nutrition (PN) from postoperative day 1 to day 5 (treatment arm), or to ERAS protocol without PN (control arm). The primary endpoint of the trial is the complication burden within 90 days after the day of surgery. The complication burden will be assessed by the Comprehensive Complication Index, that incorporates all complications and their severity as defined by the Clavien-Dindo classification, and summarizes postoperative morbidity with a numerical scale ranging from 0 to 100. The H0 hypothesis tested is that he administration of a parenteral nutrition added to the ERAS protocol will not affect the CCI as compared to standard of care (ERAS). The H1 hypothesis is that the administration of a parenteral nutrition added to the ERAS protocol will positively affect the CCI as compared to standard of care (ERAS). The trial has been registered at ClinicalTrials.gov (number: NCT04438447; date: 18/05/2020). This upcoming trial will permit to establish if early postoperative artificial nutritional support after PD may improve postoperative outcomes compared to oral nutrition alone within an established ERAS program.

Identifiants

pubmed: 37051129
doi: 10.3389/fnut.2023.1113723
pmc: PMC10083279
doi:

Banques de données

ClinicalTrials.gov
['NCT04438447']

Types de publication

Journal Article

Langues

eng

Pagination

1113723

Informations de copyright

Copyright © 2023 Gianotti, Paiella, Frigerio, Pecorelli, Capretti, Sandini and Bernasconi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Nutr. 2002 Feb;21(1):59-65
pubmed: 11884014
Pancreatology. 2013 Jan-Feb;13(1):58-62
pubmed: 23395571
Surgery. 2014 Oct;156(4):939-46
pubmed: 25151555
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
J Surg Oncol. 2013 Jun;107(7):702-8
pubmed: 23280557
Surgery. 2007 Nov;142(5):761-8
pubmed: 17981197
HPB (Oxford). 2012 Oct;14(10):700-8
pubmed: 22954007
JAMA Surg. 2017 Mar 1;152(3):292-298
pubmed: 28097305
Ann Surg. 2019 Nov;270(5):923-929
pubmed: 31592889
Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78; quiz 279-80
pubmed: 10219875
World J Surg. 2014 Nov;38(11):2960-6
pubmed: 24870390
Korean J Hepatobiliary Pancreat Surg. 2014 Aug;18(3):84-9
pubmed: 26155256
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):207-217
pubmed: 30920778
Surgery. 2018 Nov;164(5):1035-1048
pubmed: 30029989
Br J Surg. 2019 Feb;106(3):190-198
pubmed: 30724356
Front Oncol. 2021 Apr 29;11:656332
pubmed: 33996579
Clin Nutr. 2020 Jul;39(7):2014-2024
pubmed: 31699468
Ann Surg. 2013 Jul;258(1):1-7
pubmed: 23728278
Ann Surg. 2022 Dec 1;276(6):1029-1038
pubmed: 33630454
Ann Surg. 2016 Nov;264(5):731-737
pubmed: 27429039
JAMA Surg. 2022 May 1;157(5):384-393
pubmed: 35293973
Clin Nutr. 2021 Dec;40(12):5802-5811
pubmed: 34775223
Dig Surg. 2014;31(3):177-84
pubmed: 25097014
Surgery. 2007 Jul;142(1):20-5
pubmed: 17629996
JAMA Surg. 2020 Apr 1;155(4):313-321
pubmed: 32101272
Br J Surg. 2019 Aug;106(9):1138-1146
pubmed: 31241185
Br J Surg. 2013 Apr;100(5):589-98; discussion 599
pubmed: 23354970
World J Surg. 2020 Jul;44(7):2056-2084
pubmed: 32161987
Front Oncol. 2022 Jun 28;12:855784
pubmed: 35865476
Br J Surg. 2022 Feb 24;109(3):256-266
pubmed: 35037019

Auteurs

Luca Gianotti (L)

School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
HPB Unit IRCCS San Gerardo Hospital, Monza, Italy.

Salvatore Paiella (S)

General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital, Verona, Italy.

Isabella Frigerio (I)

Unit of HPB Surgery, Pederzoli Hospital, Peschiera del Garda, Italy.

Nicolò Pecorelli (N)

Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Milan, Italy.

Giovanni Capretti (G)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Pancreatic Surgery, IRCCS Humanitas Research Hospital, Rozzano, Italy.

Marta Sandini (M)

Surgical Oncology Unit, Department of Medical, Surgical, and Neurologic Sciences, Policlinico Le Scotte, University of Siena, Siena, Italy.

Davide Paolo Bernasconi (DP)

Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Classifications MeSH